Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2022

Open Access 01-12-2022 | Radiotherapy | Research

Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis

Authors: Zesheng Zeng, Shengen Xu, Dingting Wang, Gang Qin

Published in: Systematic Reviews | Issue 1/2022

Login to get access

Abstract

Background

Previous studies have investigated the prognostic value of the systemic immune-inflammation index (SII) in nasopharyngeal carcinoma (NPC). However, the results have been inconsistent. Therefore, this study aims to investigate the prognostic significance of SII in NPC through a meta-analysis.

Methods

The PubMed, Web of Science, Embase, and Cochrane Library databases were thoroughly searched. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the prognostic value of the SII for survival outcomes.

Results

A total of six studies comprising 2169 patients were included in the meta-analysis. Pooled analyses indicated that a high SII was significantly associated with worse overall survival (OS) (HR = 1.69, 95% CI = 1.36–2.09, P < 0.001) and progression-free survival (PFS) (HR = 1.60, 95% CI = 1.29–1.98, P < 0.001) in patients with NPC. Subgroup analysis showed that SII was a significant prognostic marker for PFS but not for OS in NPC.

Conclusion

Our meta-analysis demonstrated that a high SII could be an efficient prognostic indicator of OS and PFS in NPC. In our opinion, SII could be used to predict long-term and short-term outcomes in patients with NPC. Furthermore, we suggest that SII be applied to help individual patients with NPC assess the prognostic risk.

Systematic review registration

PROSPERO CRD42022321570
Literature
1.
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80.CrossRefPubMed
2.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
3.
4.
Tang LL, Huang CL, Zhang N, Jiang W, Wu YS, Huang SH, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479–90.CrossRefPubMed
5.
Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53(1):12–22.CrossRefPubMed
6.
Wang L, Wu Z, Cheng W, Xie D, Lin F, Xia L, et al. Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up. Radiat Oncol. 2021;16(1):215.CrossRefPubMedPubMedCentral
7.
Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019;145(1):295–305.CrossRefPubMed
8.
Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–64.CrossRefPubMed
9.
10.
Liu YY, Ruan GT, Ge YZ, Li QQ, Zhang Q, Zhang X, et al. Systemic inflammation with sarcopenia predicts survival in patients with gastric cancer. J Cancer Res Clin Oncol. 2022.
11.
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.CrossRefPubMed
12.
Li X, Lin H, Ouyang R, Yang Y, Peng J. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis. Biosci Rep. 2021;41(8).
13.
Zhang H, Shang X, Ren P, Gong L, Ahmed A, Ma Z, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol. 2019;234(2):1794–802.CrossRefPubMed
14.
Wang Q, Zhu D. The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. J Gastrointest Oncol. 2019;10(5):965–78.CrossRefPubMedPubMedCentral
15.
Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg. 2019;270(1):139–46.CrossRefPubMed
16.
Li M, Li Z, Wang Z, Yue C, Hu W, Lu H. Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis. Clin Exp Med. 2022.
17.
Zhu M, Chen L, Kong X, Wang X, Li X, Fang Y, et al. The systemic immune-inflammation index is an independent predictor of survival in breast cancer patients. Cancer Manag Res. 2022;14:775–820.CrossRefPubMedPubMedCentral
18.
Fu F, Deng C, Wen Z, Gao Z, Zhao Y, Han H, et al. Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(7):3144–54.CrossRefPubMedPubMedCentral
19.
Zhou Y, Dai M, Zhang Z. Prognostic significance of the systemic immune-inflammation index (SII) in patients with small cell lung cancer: a meta-analysis. Front Oncol. 2022;12:814727.CrossRefPubMedPubMedCentral
20.
Kubota K, Ito R, Narita N, Tanaka Y, Furudate K, Akiyama N, et al. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment. Bmc Cancer. 2022;22(1):368.CrossRefPubMedPubMedCentral
21.
Jiang W, Chen Y, Huang J, Xi D, Chen J, Shao Y, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. Oncotarget. 2017;8(39):66075–86.CrossRefPubMedPubMedCentral
22.
Oei RW, Ye L, Kong F, Du C, Zhai R, Xu T, et al. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study. Cancer Manag Res. 2018;10:2785–97.CrossRefPubMedPubMedCentral
23.
Lin C, Lin S, Guo QJ, Zong JF, Lu TZ, Lin N, et al. Systemic immune-inflammation index as a prognostic marker in patients with newly diagnosed metastatic nasopharyngeal carcinoma: a propensity score-matched study. Transl Cancer Res. 2019;8(5):2089–98.CrossRefPubMedPubMedCentral
24.
Feng Y, Zhang N, Wang S, Zou W, He Y, Ma JA, et al. Systemic inflammation response index is a predictor of poor survival in locally advanced nasopharyngeal carcinoma: a propensity score matching study. Front Oncol. 2020;10:575417.CrossRefPubMedPubMedCentral
25.
Zeng X, Liu G, Pan Y, Li Y. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–49.CrossRefPubMedPubMedCentral
26.
Li Q, Yu L, Yang P, Hu Q. Prognostic value of inflammatory markers in nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. Cancer Manag Res. 2021;13:6799–810.CrossRefPubMedPubMedCentral
27.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9, w64.
28.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
29.
Reeves BC, Deeks JJ, Higgins JP, Wells GA. Including non-randomized studies. 2008:Cochrane Handb Syst Rev Interv Chapter 13.
30.
Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112–9.CrossRefPubMed
31.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.CrossRefPubMed
32.
Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2020;99(1):e18571.CrossRefPubMedPubMedCentral
33.
Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224.CrossRefPubMedPubMedCentral
34.
Li X, Gu L, Chen Y, Chong Y, Wang X, Guo P, et al. Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. Ann Med. 2021;53(1):1827–38.CrossRefPubMedPubMedCentral
35.
Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic immune-inflammation index in gastric cancer: a meta-analysis. Front Oncol. 2021;11:537140.CrossRefPubMedPubMedCentral
36.
Shui Y, Li M, Su J, Chen M, Gu X, Guo W. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging (Albany NY). 2021;13(16):20585–97.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic significance of systemic immune-inflammation index in patients with nasopharyngeal carcinoma: a meta-analysis
Authors
Zesheng Zeng
Shengen Xu
Dingting Wang
Gang Qin
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Radiotherapy
Published in
Systematic Reviews / Issue 1/2022
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-022-02123-y

Other articles of this Issue 1/2022

Systematic Reviews 1/2022 Go to the issue

Protocol

Honorary authorship in health sciences: a protocol for a systematic review of survey research

Research

Management of symptomatic cholelithiasis: a systematic review

Research

Quality of life and complications after nephron-sparing treatment of renal cell carcinoma stage T1—a systematic review

Research

The hemostatic effect of hot saline irrigation in endoscopic sinus surgery: a systematic review and meta-analysis

Protocol

Do social relationships mediate or moderate social inequalities in health? A systematic review protocol

Protocol

Effectiveness of multicomponent treatment in patients with fibromyalgia: protocol for a systematic review and meta-analysis